Publikation:

CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues

Lade...
Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2021

Autor:innen

Yu, Xiaobing
Munoz-Sagredo, Leonel
Streule, Karolin
Muschong, Patricia
Bayer, Elisabeth
Walter, Romina J.
Greil, Richard
Concha, Miguel L.
Müller-Tidow, Carsten
et al.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Blood. American Society of Hematology. 2021, 138(12), pp. 1067-1080. ISSN 0006-4971. eISSN 1528-0020. Available under: doi: 10.1182/blood.2020006343

Zusammenfassung

Acute myeloid leukemia (AML) has a poor prognosis under the current standard of care. In recent years, venetoclax, a BCL-2 inhibitor, was approved to treat patients who are ineligible for intensive induction chemotherapy. However, complete remission rates with venetoclax-based therapies are hampered by minimal residual disease (MRD) in a proportion of patients, leading to relapse. MRD is a result of leukemic stem cells being retained in bone marrow protective environments; activation of the CXCL12-CXCR4 pathway was shown to be relevant to this process. An important role is also played by cell adhesion molecules such as CD44, which has been shown to be crucial for the development of AML. Here we show that CD44 is involved in CXCL12 promotion of resistance to venetoclax-induced apoptosis in human AML cell lines and AML patient samples, which could be abrogated by CD44 knock down, knockout, or blocking with an anti-CD44 antibody. Split-Venus bimolecular fluorescence complementation showed that CD44 and CXCR4 physically associate at the cell membrane upon CXCL12 induction. In the venetoclax-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors (ESC-TFs: Sox2, Oct4, Nanog) abrogated by CD44 knockdown. This ESC-TF–expressing subpopulation which could be selected by venetoclax treatment, exhibited a basally enhanced resistance to apoptosis and expressed higher levels of CD44. Finally, we developed a novel AML xenograft model in zebrafish, which showed that CD44 knockout sensitizes OCI-AML3 cells to venetoclax treatment in vivo. Our study shows that CD44 is a potential molecular target for sensitizing AML cells to venetoclax-based therapies.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690YU, Xiaobing, Leonel MUNOZ-SAGREDO, Karolin STREULE, Patricia MUSCHONG, Elisabeth BAYER, Romina J. WALTER, Julia C. GUTJAHR, Richard GREIL, Miguel L. CONCHA, Carsten MÜLLER-TIDOW, 2021. CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues. In: Blood. American Society of Hematology. 2021, 138(12), pp. 1067-1080. ISSN 0006-4971. eISSN 1528-0020. Available under: doi: 10.1182/blood.2020006343
BibTex
@article{Yu2021-06-03funct-68990,
  year={2021},
  doi={10.1182/blood.2020006343},
  title={CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues},
  number={12},
  volume={138},
  issn={0006-4971},
  journal={Blood},
  pages={1067--1080},
  author={Yu, Xiaobing and Munoz-Sagredo, Leonel and Streule, Karolin and Muschong, Patricia and Bayer, Elisabeth and Walter, Romina J. and Gutjahr, Julia C. and Greil, Richard and Concha, Miguel L. and Müller-Tidow, Carsten}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/68990">
    <dc:contributor>Streule, Karolin</dc:contributor>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:contributor>Yu, Xiaobing</dc:contributor>
    <dc:contributor>Greil, Richard</dc:contributor>
    <dc:contributor>Walter, Romina J.</dc:contributor>
    <dcterms:abstract>Acute myeloid leukemia (AML) has a poor prognosis under the current standard of care. In recent years, venetoclax, a BCL-2 inhibitor, was approved to treat patients who are ineligible for intensive induction chemotherapy. However, complete remission rates with venetoclax-based therapies are hampered by minimal residual disease (MRD) in a proportion of patients, leading to relapse. MRD is a result of leukemic stem cells being retained in bone marrow protective environments; activation of the CXCL12-CXCR4 pathway was shown to be relevant to this process. An important role is also played by cell adhesion molecules such as CD44, which has been shown to be crucial for the development of AML. Here we show that CD44 is involved in CXCL12 promotion of resistance to venetoclax-induced apoptosis in human AML cell lines and AML patient samples, which could be abrogated by CD44 knock down, knockout, or blocking with an anti-CD44 antibody. Split-Venus bimolecular fluorescence complementation showed that CD44 and CXCR4 physically associate at the cell membrane upon CXCL12 induction. In the venetoclax-resistant OCI-AML3 cell line, CXCL12 promoted an increase in the proportion of cells expressing high levels of embryonic stem cell core transcription factors (ESC-TFs: Sox2, Oct4, Nanog) abrogated by CD44 knockdown. This ESC-TF–expressing subpopulation which could be selected by venetoclax treatment, exhibited a basally enhanced resistance to apoptosis and expressed higher levels of CD44. Finally, we developed a novel AML xenograft model in zebrafish, which showed that CD44 knockout sensitizes OCI-AML3 cells to venetoclax treatment in vivo. Our study shows that CD44 is a potential molecular target for sensitizing AML cells to venetoclax-based therapies.</dcterms:abstract>
    <dc:contributor>Munoz-Sagredo, Leonel</dc:contributor>
    <dcterms:title>CD44 loss of function sensitizes AML cells to the BCL-2 inhibitor venetoclax by decreasing CXCL12-driven survival cues</dcterms:title>
    <dc:creator>Yu, Xiaobing</dc:creator>
    <dc:creator>Muschong, Patricia</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:creator>Walter, Romina J.</dc:creator>
    <dc:creator>Müller-Tidow, Carsten</dc:creator>
    <dc:creator>Greil, Richard</dc:creator>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/68990"/>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-10T08:44:24Z</dc:date>
    <dc:contributor>Bayer, Elisabeth</dc:contributor>
    <dc:creator>Concha, Miguel L.</dc:creator>
    <dc:creator>Munoz-Sagredo, Leonel</dc:creator>
    <dc:contributor>Muschong, Patricia</dc:contributor>
    <dc:creator>Streule, Karolin</dc:creator>
    <dc:language>eng</dc:language>
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Bayer, Elisabeth</dc:creator>
    <dc:contributor>Gutjahr, Julia C.</dc:contributor>
    <dcterms:issued>2021-06-03</dcterms:issued>
    <dc:contributor>Concha, Miguel L.</dc:contributor>
    <dc:creator>Gutjahr, Julia C.</dc:creator>
    <dc:contributor>Müller-Tidow, Carsten</dc:contributor>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2024-01-10T08:44:24Z</dcterms:available>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Nein
Begutachtet
Ja
Diese Publikation teilen